SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

AML/MDS
CD33 Expressing Hematological Malignancies
FLT3 Expressing Hematological Malignancies

Interventions

BIOLOGICAL: SENTI-202

Sponsor

Senti Biosciences